Pancreas Cancer Clinical Trials 2024

What are the top hospitals conducting pancreas cancer research?

Pancreatic cancer, a formidable opponent in the realm of oncology, has captured the attention of top hospitals across North America. In Boston, Massachusetts General Hospital leads the charge with three active clinical trials focused on this relentless disease. Having conducted an impressive 49 pancreas cancer trials to date since their pioneering trial in 1998, this renowned institution demonstrates its unwavering commitment to combating this challenging condition. Meanwhile, in New york City's Memorial Sloan Kettering Cancer Center—an institution known for its cutting-edge research—scientists are currently engaged in three pancreatic cancer trials while having achieved an admirable tally of 44 all-time studies since embarking upon their first trial in 2006.

Venturing northward to Edmonton, Canada, the Cross Cancer Institute is making significant strides with its three ongoing pancreas cancer trials and noteworthy contribution of sixteen past investigations. This institute joined forces against pancreatic cancer alongside Massachusetts General Hospital as they both initiated their initial study on it back during late nineties around1998.

In Tampa's Moffitt Cancer Center and Durham's Duke University Medical Center also spearhead efforts towards conquering pancreatic cancer. These institutions have each embarked upon two active clinical trials while accumulating respective totals of twenty-five and twenty-one past endeavors dedicated to unraveling the mysteries surrounding this aggressive disease. Remarkably commencing their earliest recorded pancreas trial - Moffit Cancer Centre commenced doing so during two thousand nine(2009) whilst Duke University had started conducting such similar tests five years prior or precisely from year two thousand four.

These exceptional medical centers not only provide hope for individuals battling pancreatic cancer but also serve as beacons within the realm of medical research worldwide. Their collective determination underscores that every scientific inquiry counts towards improving patient outcomes and bringing us closer to finding effective treatment options for those affected by this insidious disease.

Which are the best cities for pancreas cancer clinical trials?

When it comes to pancreas cancer clinical trials, several cities in the United States are at the forefront of research. New york City leads with 11 active trials studying treatments like LY3537982, brigimadlin (BI 907828) treatment arm, and NUV-868. Houston, Texas and Nashville, Tennessee both have 6 ongoing trials investigating potential therapies such as A2530, PT199, and TC-510. Meanwhile, Los Angeles and Baltimore each have 5 active trials exploring treatments including EUS with Fiducial markers and Pembrolizumab. These cities offer individuals diagnosed with pancreas cancer access to cutting-edge clinical trials that may contribute to improved treatment options and outcomes for this challenging disease.

Which are the top treatments for pancreas cancer being explored in clinical trials?

Pancreas cancer research is making strides, with two promising treatments currently in clinical trials. SGN-BB228, a newly introduced therapy listed in 2023, shows potential and is being tested in one active trial for pancreas cancer. Similarly, PT199 has also grabbed attention as it undergoes evaluation in one ongoing trial. Both treatments hold promise and offer hope for patients battling this challenging disease. As researchers delve deeper into these trials, the path to improved outcomes becomes clearer for those affected by pancreatic cancer.

What are the most recent clinical trials for pancreas cancer?

Exciting developments are unfolding in the realm of pancreas cancer research, creating new avenues for potential treatment. The most recent clinical trials include a Phase 4 trial examining the effectiveness of PDAC with HA Chemotherapy for this aggressive form of cancer. Additionally, a Phase 2 trial investigates Tislelizumab and SX-682 as a promising combination therapy option. Part B Expansion is also underway to explore novel approaches to combat pancreas cancer through a Phase 1 study. Furthermore, an innovative trial named A2530 assesses the efficacy of multiple phases in treating this challenging disease. Finally, researchers are rigorously evaluating standard-of-care protocols through an ongoing Phase 3 study to ensure optimal patient outcomes. These collective efforts bring hope and progress towards improving treatments for individuals affected by pancreas cancer

What pancreas cancer clinical trials were recently completed?

Numerous clinical trials investigating potential treatments for pancreas cancer have recently been concluded, showcasing the ongoing efforts to combat this challenging disease. In December 2021, CanBas Co. Ltd. successfully completed a trial evaluating the effectiveness of Cisplatin in treating pancreatic cancer patients. Other notable trials include Dapagliflozin, sponsored by Washington University School of Medicine and completed in February 2021; Plerixafor, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and completed in November 2020; and Dostarlimab, sponsored by Massachusetts General Hospital and completed in July 2020. These recent advancements highlight the dedication of researchers striving to find innovative solutions for pancreatic cancer treatment options.